Sales · healthcare · North AmericaJul 202610 min read373 words

Modern cold calling for Series B companies: scaling without breaking for healthcare and life sciences in North America

How Series B companies scale modern cold calling across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in North America.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in North America. In this market, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed, so the way you install modern cold calling has to be shaped to that reality from day one.

Series B is the stress test for modern cold calling. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, connects per hour on ICP dials, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in North America it is compounded by the fact that signal above noise, not lead volume is what actually gates growth. Modern cold calling is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of modern cold calling is power dialers that torch the list in a week, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on connects per hour on ICP dials outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run modern cold calling function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in North America: the healthcare teams that install this get past procurement instead of dying in it, and the North American teams that install this land inside the first quarter, not the fourth. That is the reason it is worth installing modern cold calling deliberately for this market rather than importing a playbook designed for somewhere else.

cold callingoutbound callingphone prospectingcold calling for series Bscaling GTMcold calling for healthcare and life sciencescold calling in North Americahealthcare and life sciences growth in North America

Frequently asked questions

Sales · healthcare · North America — answered

Does modern cold calling work for healthcare and life sciences in North America?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in North America, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed. The healthcare teams that install this get past procurement instead of dying in it.
How does modern cold calling change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible connects per hour on ICP dials.
What compensation model works for modern cold calling operators at Series B?
Outcome-linked on connects per hour on ICP dials, not activity-based.
What is the Series B stress point?
Power dialers that torch the list in a week, amplified by headcount. Fix the root, not the symptom.
What is the North America-specific pitfall when running modern cold calling for healthcare?
Importing a playbook that was built for another market. In North America, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed — the install has to reflect that.

Growth Broker editorial

Filed under sales · healthcare · north america

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call